Bristol Myers Squibb has become the first life sciences company to purchase NVIDIA's newest AI supercomputing blueprint, announcing plans to build what it calls the pharmaceutical industry's most powerful centralized AI factory on the chipmaker's Vera Rubin platform. The deal marks a significant escalation in the AI arms race underway across the drug development sector. For continuous coverage of the AI developments reshaping industries worldwide, AI Buzz Wire brings you the stories that matter.
The US pharmaceutical giant is deploying an NVIDIA DGX SuperPOD built on the Vera Rubin NVL72 system, a next-generation AI and supercomputing platform designed specifically for complex, autonomous agentic AI workflows and scientific computing. The system is named after Vera Cooper Rubin, the acclaimed astronomer whose work provided foundational evidence for the existence of dark matter.
A Step Change in Computational Power
According to BMS, the deployment will deliver the most advanced and most energy-efficient NVIDIA infrastructure in life sciences, operating with up to ten times greater performance per megawatt than predecessor systems. That efficiency claim is critical at a time when AI's energy appetite has become a central concern for both industry and policymakers.
The company said the new infrastructure will allow it to pursue larger and more sophisticated AI workloads without a proportional increase in energy consumption, scaling proprietary AI models designed to truncate drug discovery timelines and improve research outcomes.
BMS frames the investment as the backbone of its hybrid intelligence vision, a strategy in which AI systems work alongside human researchers rather than replacing them. The goal is to let scientists spend less time on repetitive computational tasks and more time on the questions that require genuine scientific judgment.
AI Already Embedded in BMS Drug Programs
The announcement is not a forward-looking aspiration disconnected from current operations. BMS says artificial intelligence already informs the design of every small molecule program in its pipeline, and the majority of its large molecule programs. The company describes this as a predict-first approach, in which AI-generated models shape hypotheses before any laboratory work begins.
AI agents at BMS already automate target identification and validation, tasks that previously consumed weeks of manual effort by research scientists. Those agents now free researchers to focus on hypothesis testing and higher-level scientific decisions, the company said.
Greg Meyers, chief digital and technology officer at BMS, said the company has been building toward this project for nearly three years. "BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations," Meyers said in a statement. "Expanding our compute capabilities with NVIDIA gives our researchers and teams across the business the scale they need to keep BMS at the leading edge of what AI can do for drug discovery and development."
Betting on Better Decisions, Not Just Speed
Robert Plenge, BMS's chief research officer, framed the investment as fundamentally about improving the quality of scientific decisions rather than simply accelerating them. "Drug discovery is a sequence of decisions made under uncertainty, and better decisions come from better evidence, faster," Plenge said. "This infrastructure lets us learn from every experiment and every clinical readout to sharpen the next hypothesis, allowing BMS scientists to spend less time on manual work and more time on the questions that require human judgment."
"The goal isn't speed for its own sake," Plenge added. "It's raising the probability that each programme we advance is the right one."
The financial terms of the deal were not disclosed.
A Pharmaceutical AI Arms Race
BMS's announcement comes amid a wave of similar investments across the pharmaceutical sector, signaling that AI-driven drug discovery has moved from experimental pilot programs to core infrastructure spending. Just months earlier, Eli Lilly made comparable claims on the back of its own partnership with NVIDIA, asserting that no other company was operating at the scale of its AI computing project.
Drug discovery using AI is being championed as a way to shorten the time to lead candidate selection, reduce development costs, and improve success rates. The technology's ability to process vast datasets, uncover hidden patterns, and generate testable predictions has made it increasingly attractive for identifying new drug targets and designing novel therapeutic compounds.
The pharmaceutical industry's embrace of large-scale AI computing also underscores a broader trend: the companies building AI infrastructure are no longer just technology firms. From drug discovery to materials science, the most consequential AI deployments are increasingly happening inside traditional industries that are racing to embed computational intelligence into their core processes.
For BMS, the bet is that being first to NVIDIA's newest platform will translate into a durable research advantage. Whether that advantage holds will depend on whether the AI models running on Vera Rubin can consistently produce better drug candidates — and ultimately, better medicines for patients.
Stay Ahead of the AI Frontier
From pharmaceutical research labs to semiconductor foundries, AI is rewriting the rules across every industry. Bookmark AI Buzz Wire for the latest reporting on how artificial intelligence is transforming the world.
Read more AI news →
